Bioregulators Khavinson bioregulator tripeptideNot FDA-approved · research compound

Ovagen

Ovagen (Khavinson)

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

10-50 mcg daily SubQ 10-20 day course, 2-3x per year

10-20 mg Oral Daily

Liver/GI tissue regulatorHepatic and digestive gene modulator

Ovagen (Lys-Glu-Asp) is a Khavinson bioregulator tripeptide targeting liver and gastrointestinal tissue gene expression. It overlaps with Livagen (liver-focused) but has broader hepatic and GI tissue targeting. Supports hepatocyte function, GI epithelial maintenance, and digestive system health.

Quick Start

Route

SubQ injection

Start low

10-50 mcg SubQ

Frequency

10-20 day course, 2-3x per year

Timing

No fasting required

Starting dose. 10-50 mcg — Daily

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

10-50 mcg daily · SubQ injection · 10-20 day course, 2-3x per year

conservative starter

10-50 mcg daily

10-20 day course, 2-3x per year

Standard

Liver Regeneration (Oral capsule)

10-20 mg · Oral · Daily

anecdotal · community

Synthetic liver bioregulator. Cycle for 10-20 days. This is the ORAL capsule dose and is not an injection dose. Oral peptide absorption is poor, so this figure is far higher than the injectable protocol on purpose. Do not inject this amount.

10-20 mg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

Ovagen modulates gene expression in hepatocytes and GI epithelial cells, supporting liver detoxification pathways, GI barrier integrity, and digestive enzyme production at the gene level.

What to expect

Early

Days 1–7

Days 1-10: Gene changes initiated.

Mid

Weeks 2–4

Weeks 2-8: Hepatic/GI gene programs established.

Later

Weeks 4–12

Months: Sustained support.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 10-50 mcg daily via SubQ injection, 10-20 day course, 2-3x per year. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.

Mechanism: Ovagen modulates gene expression in hepatocytes and GI epithelial cells, supporting liver detoxification pathways, GI barrier integrity, and digestive enzyme production at the gene level.. No checked live abstract supported this full mechanistic claim at the card's formulation/route without extrapolation.

Primary safety claim: Very well tolerated. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.

The honest take

◆

Liver/GI dual support

Bioregulatory mechanism targeting both hepatic and GI tissue gene expression.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

◆

Pin alone. Ovagen must not share a syringe with anything else, whatever the pharmacology says. PIN ALONE.

Documented together

BPC-157Ovagen targets liver/GI gene expression, BPC-157 drives GI mucosal repair. Complementary. Pin separately.

LivagenBoth target hepatic tissue. Can run in sequence for extended liver support.

Keep separate

GHK-CuCopper degrades bioregulators.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Very well tolerated

Less common & notes

Excellent safety profile.

Pharmacokinetics

Illustrative plasma concentration · 2.0 h

Half-life

0.5h

Peak · Tmax

0.05h

Elimination

2.5h

Bioavailability

~100%

SubQ

Duration of action

24-48 hours

Gene expression changes persist beyond peptide clearance

Clearance

Enzymatic degradation (peptidases)

Storage. Standard BAC water 2-8C. 21-28 days.

Regulatory status

Not FDA-approved. Research peptide.

Put it to work

Calculate, log & track

Open Ovagen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Ovagen in the app →

Go deeper

The guide & community

The complete Ovagen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community